关于控股股东、持股5%以上股东部分股份质押及解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 一、股东股份质押基本情况 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：301331 证券简称：恩威医药 公告编号：2025-055 恩威医药股份有限公司 ■ 上述股东及其一致行动人累计质押股份数量占其所持公司股份数量比例超过50%，现就相关情况说明如 下： 1、本次股份质押不用于满足上市公司生产经营需求； 2、恩威集团及其一致行动人未来半年内到期的累计质押股份数量为14,140,836股，占其所持公司股份的 19.89%，占公司总股本的13.74%，对应融资余额为16,000万元；未来一年内到期的累计质押股份数量为 54,420,836 股，占其所持公司股份的76.54%，占公司总股本的52.89%，对应融资余额为55,600万元。公 司及其一致行动人具备相应的资金偿还能力，还款资金来源为自有及自筹资金。 3、截至本公告披露日，上述股东及其一致行动人不存在非经营性资金占用、违规担保等侵害上市公司 利益的情形； 4、上述股东及其一致行动人股 ...

格隆汇11月27日丨金石亚药(300434.SZ)在投资者互动平台表示，公司是国内感冒药一线产品"快 克"和"小快克"的品牌缔造者和拥有者。经过二十多年的品牌积累，已经成功搭建围绕成人及儿童感咳 领域的产品集群。其中，重点产品有"快克"复方氨酚烷胺胶囊适用于缓解普通感冒及流行性感冒的各种 症状，也可用于流行性感冒的预防和治疗；"小快克"小儿氨酚黄那敏颗粒适用于缓解儿童普通感冒及流 行性感冒引起的各种症状；"快克清"磷酸奥司他韦胶囊适用于成人和1岁及1岁以上儿童的甲型和乙型流 感治疗以及成人和13岁及13岁以上青少年的甲型和乙型流感的预防。此外，还有愈美甲麻敏糖浆、蒲地 蓝消炎片、抗病毒口服液、复方金银花颗粒、感冒清热颗粒、布洛伪麻片、枇杷止咳颗粒、布洛芬颗 粒、小儿咳喘灵颗粒、板蓝根颗粒等多个产品，满足消费者预防、缓解、治疗感冒的多方面需求。 ...

（原标题：创业板大涨 沪指回落！下一任美联储主席浮出水面） 今天的市场，指数略微回落，沪指午后翻绿，一起回顾下发生了什么事情。 创业板大涨 11月26日，沪指全天窄幅震荡，创业板指涨超2%。截至收盘，沪指跌0.15%，深成指涨1.02%，创业板指涨2.14%。 市场共1692只个股上涨，76只个股涨停，3593只个股下跌。 医药股全天强势，广济药业、北大医药等涨停。消息面上，多家电商平台发布流感类药品成交数据。阿里健康平台数据显示，近两周（11.10- 11.23）流感应季药品的关注度和购买量均有明显提升。总体而言，流感抗病毒药物购买人数呈现超500%的环比增长。其中玛巴洛沙韦表现尤为 突出，购买人数环比增长超600%，增速领先；抗病毒口服液购买人数环比增长50%。反映出消费者对流感的防治意识进一步增强。 大消费板块尾盘拉升，国光连锁、三江购物等涨停。消息面上，工业和信息化部、国家发展改革委、商务部、文化和旅游部、中国人民银行、市 场监管总局印发《关于增强消费品供需适配性进一步促进消费的实施方案》。 下跌方面，军工板块集体调整，久之洋、江龙船艇等跌超10%。 美联储的大消息 知情人士透露，随着为美联储物色新主 ...

【导读】创业板大涨，沪指回落；下一任美联储主席浮出水面 中国基金报记者 泰勒 大家好，今天的市场，指数略微回落，沪指午后翻绿，一起回顾下发生了什么事情。 创业板大涨 11月26日，沪指全天窄幅震荡，创业板指涨超2%。截至收盘， 沪指跌0.15%，深成指涨1.02%，创业板指涨2.14%。 市场 共1692只个股上涨，76只个股涨停，3593只个股下跌。 | 880005 张跌家数 | | | | --- | --- | --- | | 直中 | 涨停 | 76 | | 涨幅 | > 7% | 110 | | 涨幅 | 5-7% | 74 | | 涨幅 | 3-5% | 153 | | 涨幅 | 0-3% | 1355 | | 跌幅 | 0-3% | 3259 | | 跌幅 | 3-5% | 233 | | 跌幅 | 5-7% | 64 | | 跌幅 | > 7% | 37 | | 其中 跌停 | | 6 | | | | 1692 | | | | 3593 | | 上課貸 千葉県 鮮和伊斯 | | 168 | | | | 2453 | | | | 17971.90 乙 | | 总成交量 | | 115032.0 ...

A股三大指数今日涨跌不一，截至收盘，沪指跌0.15%报3864点，深证成指涨1.02%，创业板指涨2.14%。全市场成交额1.8万亿元，较前一交易日 缩量290亿元，近3600股下跌。 | 应在后 | 名称 | 现价 | 涨跌 | 涨幅 | | --- | --- | --- | --- | --- | | 000001 | 上证指数 | 3864.18 | -5.84 | -0.15% | | 399001 | 深证成指 | 12907.83 +130.52 +1.02% | | | | 399006 | 创业板指 | 3044.69 +63.76 | | +2.14% | | 代码 名称 | 张唱� | 张庆 | 规价 | | --- | --- | --- | --- | | 301111 粤万年青 | +20.02% | +3.68 | 22.06 | | 301408 华人健康 | +20.00% | +2.90 | 17.40 | | 688670 金迪克 | +20.00% | +5.15 | 30.90 | | 000078 海王生物 | +10.20% +0.26 | | 2.81 | | ...

Group 1 - Alibaba Health (00241) shares increased by nearly 3%, currently trading at 6.1 HKD with a transaction volume of 499 million HKD [1] - There is a significant rise in demand for flu-related medications on Alibaba Health's platform, with a more than 500% week-on-week increase in the number of buyers for antiviral drugs [1] - The drug Mabalosavir showed exceptional performance, with a more than 600% increase in the number of buyers compared to the previous week [1] Group 2 - The flu season has started earlier this year, with a rapid increase in flu activity nationwide, particularly in Beijing, which has entered a high incidence period for respiratory infectious diseases [1] - According to Everbright Securities, the demand for cold medications is expected to exceed market expectations in Q4 2025, as flu cases rise with the drop in temperatures [1] - The recent increase in flu cases is likely to raise public and market awareness, driving demand for flu prevention and testing products [1]

Core Viewpoint - Alibaba Health (00241) has seen a nearly 3% increase in stock price, attributed to a significant rise in demand for flu-related medications on its platform as the flu season approaches [1] Group 1: Stock Performance - Alibaba Health's stock price rose by 2.01%, reaching 6.1 HKD, with a trading volume of 499 million HKD [1] Group 2: Demand for Flu Medications - There has been a notable increase in the demand for flu medications on Alibaba Health's platform, with a more than 500% week-on-week growth in the number of buyers for antiviral drugs [1] - Specifically, the drug Mabalosavir has seen a remarkable increase, with buyer numbers growing over 600% week-on-week, leading the growth [1] - Oral antiviral liquid medications also experienced a 50% week-on-week increase in buyer numbers, indicating heightened consumer awareness regarding flu prevention and treatment [1] Group 3: Market Trends and Projections - According to reports, flu activity has rapidly increased nationwide since November, with Beijing entering a high incidence period for respiratory infectious diseases [1] - Everbright Securities forecasts that as temperatures drop, flu cases will rise significantly, potentially increasing public and market attention on flu prevention and testing products [1] - The demand for cold medications is expected to peak in Q4 2025, with sales and shipments likely to see a turnaround, surpassing market expectations due to the current upward trend in flu cases [1]

Core Viewpoint - The flu-related stocks in the A-share market are experiencing significant activity, driven by a surge in demand for flu medications and testing services as the flu season peaks in various regions of China [1] Group 1: Stock Performance - Yue Wannianqing saw a rise of over 16%, while Kangzhi Pharmaceutical increased by over 12%, and Hainan Haiyao and Peking University Pharmaceutical achieved consecutive gains [1] - The stock performance of flu-related companies indicates a strong market response, with notable increases in share prices for several firms [2] Group 2: Market Demand - Demand for flu-related medications and online consultations has surged, particularly in Northeast, North China, and Northwest regions, with Southern cities also experiencing rapid growth [1] - Orders for specific antiviral medications have more than doubled since November, with Mabalosavir tablets increasing by over 110% and Oseltamivir phosphate granules by over 85% compared to the previous month [1] Group 3: Consumer Behavior - Data from Alibaba Health shows a significant increase in the attention and purchase volume of flu medications over the past two weeks, with a more than 500% increase in the number of buyers for antiviral drugs [1] - Mabalosavir has shown exceptional growth, with a 600% increase in the number of purchasers, indicating heightened consumer awareness regarding flu prevention and treatment [1]

Core Viewpoint - The flu-related stocks in the A-share market are experiencing significant activity, driven by a surge in demand for flu medications and testing, particularly in northern regions of China [1] Group 1: Market Activity - Flu concept stocks are active, with notable increases in share prices: Yue Wannianqing up over 16%, Kangzhi Pharmaceutical up over 12%, and Hainan Haiyao and Peking University Pharmaceutical achieving consecutive gains [1] - The demand for flu-related medications and online consultations has risen sharply, with a more than 100% increase in orders for specific antiviral drugs since November [1] Group 2: Sales Data - Orders for the antiviral drug Mabalosavir have increased by over 110% compared to the previous month, while orders for Oseltamivir phosphate granules have risen by over 85% [1] - The sales of flu testing kits have shown a month-on-month increase of over 900% [1] Group 3: Consumer Behavior - Data from Alibaba Health indicates a significant rise in the attention and purchase volume of flu season medications, with a more than 500% increase in the number of buyers for antiviral drugs [1] - Mabalosavir stands out with a purchase increase of over 600%, while the number of buyers for antiviral oral solutions has risen by 50% [1]

A 天天基金 链接您与财富 美版材梳理 7 3 = 近期,随着各省份逐渐入冬,全国多地流感活动进入上升期。 机构表示,秋冬季流感高峰到来,有望带动流感疫苗、呼吸 道检测、流感用药、用药终端等细分方向的需求增长。 | 流感疫苗 | 检测服务 | | | --- | --- | --- | | 华兰疫苗 | 仁度生物 九安医疗 | | | 华兰生物 | 达安基因 | 万孚生物 | | 百克生物 | 圣湘生物 | 之江生物 | | 金迪克 | 东方生物 | 英诺特 | | 零售药店 | 流感用药 | | | 益丰药房 | 众生药业 | 华润三九 | | 漱玉平民 | 济川药业 | 特一药业 | | ##十 | NING W | 左阳斗左 | | 八学师 | NAREN THE SEY | | | --- | --- | --- | | -心草 | 方盛制药 | 金石亚药 | | 老百姓 | 健康元 | 自玄山 | | 健之佳 | 康恩贝 | HE | | 基金名称 | 近1年收益 | 成立来收益 | | --- | --- | --- | | 安信医药健康股票A | 51.37% | 49.70% | | 前海开源 ...